The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum is a translational science meeting focusing on scientific discoveries made in multiple sclerosis (MS) to advance the understanding of research and clinical care of patients with MS.
Balancing Efficacy and Safety With MS Disease-Modifying Therapies: Omar Al-Louzi, MDMarch 17th 2023
The director of the Visual Outcomes Laboratory at Cedars Sinai talked about the current treatments used in MS and the risks associated with them at 2023 ACTRIMS Forum. [WATCH TIME: 3 minutes]
Using MRIs to Detect Early Signs of Viral Infections in Multiple SclerosisMarch 16th 2023
At the 2023 ACTRIMS forum, Omar Al-Louzi, MD, director of the Visual Outcomes Laboratory at Cedars Sinai, talked about investigating the relationship between viral infections and multiple sclerosis using MRIs.
Applying Artificial Intelligence to Monitor Multiple Sclerosis Disease ProgressionMarch 15th 2023
Michael Dwyer, PhD, director of IT and Neuroinformatics Development at the Buffalo Neuroimaging Analysis Center, provided insight on how artificial intelligence techniques may be used to monitor disease progression in multiple sclerosis.
Sustainability and Future of Intermittent Calorie Restriction in Multiple Sclerosis: Laura Piccio, MD, PhDMarch 14th 2023
The neurologist and physician scientist at Washington University in St. Louis provided perspective on the need for additional studies assessing the long-term effects of dieting strategies in multiple sclerosis. [WATCH TIME: 3 minutes]
Exploring New Therapies for MS With Research on T-bet+ memory B Cells: Rajiv Jain, PhDMarch 14th 2023
At the 2023 ACTRIMS, the post-doctoral associate in the department of clinical neurosciences at the University of Calgary, spoke on the impact of researching T-Bet+ memory B cells for new therapies in multiple sclerosis. [WATCH TIME: 5 minutes]
Promising Findings on the Role of T-bet+ Memory B Cells in MS: Rajiv Jain, PhDMarch 13th 2023
At the 2023 ACTRIMS Forum, the post-doctoral associate in the department of clinical neurosciences at the University of Calgary talked about the main findings he observed with B cell therapies in patients with MS. [WATCH TIME: 4 minutes]
Retrograde Trans-Synaptic Degeneration in MS and its Impact on Visual FunctionMarch 12th 2023
Omar Al-Louzi, MD, director of the Visual Outcomes Laboratory at Cedars Sinai, provided his clinical perspective on role of imaging and viral infections in patients with MS at the 2023 ACTRIMS forum.
Top Interviews from 2023 ACTRIMS: Expert Insights on Multiple SclerosisMarch 8th 2023
A group of experts in the care of patients with multiple sclerosis—Marisa McGinley, DO; Farrah Mateen, MD, PhD; Laura Piccio, MD, PhD; Robert Zivadinov, MD, PhD; and Bruce Cree, MD, PhD, MAS, FAAN—shared their perspectives on hot topics of treatment and management from the 2023 ACTRIMS Forum.
Proven Therapies Underutilized in State of Care for NMOSD: Bruce Cree, MD, PhD, MAS, FAANMarch 8th 2023
The clinical research director of the UCSF Multiple Sclerosis Center spoke about the barriers in accessing proven therapies for NMOSD at the 2023 ACTRIMS Forum. [WATCH TIME: 3 minutes]
Potential Therapies Targeting Memory B-Cells to Prevent Relapse and Progression in MSMarch 7th 2023
Rajiv Jain, PhD, post-doctoral associate, department of clinical neurosciences, University of Calgary, talked about his presentation on T-bet+ memory B-cells in multiple sclerosis at the 2023 ACTRIMS Forum.
Significance of Evusheld’s Effect in Multiple Sclerosis: Svetlana P. Eckert, MDMarch 7th 2023
The clinical assistant professor of neurology at Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, New York, talked about her presentation on Evusheld at the 2023 ACTRIMS Forum. [WATCH TIME: 5 minutes]
Utilizing Biomarker Panels to Effectively Gauge, Manage Multiple SclerosisMarch 6th 2023
Taylor Gonyou, DO, a multiple sclerosis fellow at Michigan Institute for Neurologic Disorders, detailed a proteomic biomarker panel that gauges multiple sclerosis disease activity, with potential to impact clinical decision-making.
Overcoming Issues With Access to MRIs, Resources in Care of Multiple Sclerosis: Robert Zivadinov, MD, PhDMarch 6th 2023
The director of the Buffalo Neuroimaging Analysis Center provide perspective on innovative ways to monitor progression in multiple sclerosis, and the importance of high-level care facilities. [WATCH TIME: 5 minutes]
Role of Evusheld in Preventing COVID Infections in Multiple SclerosisMarch 5th 2023
Svetlana P. Eckert, MD, clinical assistant professor of neurology at University at Buffalo, talked about Evusheld as a preventive approach to COVID-19 infections in multiple sclerosis at the 2023 ACTRIMS Forum.
Investigating Effectiveness of COVID-19 Vaccination in Patients on B-Cell Depleting Therapies: Bruce Cree, MD, PhD, MAS, FAANMarch 5th 2023
At the 2023 ACTRIMS Forum, the clinical research director of the UCSF Multiple Sclerosis Center talked about the implications for patients on B-cell depleting therapies infected with COVID-19. [WATCH TIME: 4 minutes]
Vaccine Status and Hypogammaglobulinemia in N-MOmentum Trial Analyses: Bruce Cree, MD, PhD, MAS, FAANMarch 3rd 2023
The clinical research director of the UCSF Multiple Sclerosis Center spoke on the findings from two post-hoc analyses that were presented at the 2023 ACTRIMS Conference. [WATCH TIME: 3 minutes]
Low Incidence of COVID-19 Infections Observed in Inebilizumab-Treated Patients With NMOSDMarch 2nd 2023
Of 2 patient fatalities in the analysis, one was unvaccinated and treated with nonconventional therapies for COVID-19 and the other had a history of deep venous thrombosis and was complicated by pulmonary embolism.
Assessing Deep Gray Matter Loss in Cortical, Thalamic Regions to Understand MS Progression: Robert Zivadinov, MD, PhDMarch 2nd 2023
The director of the Buffalo Neuroimaging Analysis Center discussed the need to further explain differences in cortical lesions and deep gray matter in patients with severely affected multiple sclerosis. [WATCH TIME: 4 minutes]
Implications of Post-hoc Analyses of N-MOmentum Trial in Inebilizumab and Future ThoughtsMarch 2nd 2023
Bruce Cree, MD, PhD, MAS, FAAN, clinical research director of the UCSF Multiple Sclerosis Center provided insight on 2 post-hoc analyses of the N-MOmentum trial for NMOSD that were presented at 2023 ACTRIMS Forum.
Challenges With Tailoring Diets in Multiple Sclerosis: Laura Piccio, MD, PhDMarch 1st 2023
The neurologist and physician scientist at Washington University in St. Louis provided insight on the general dieting strategies patients with multiple sclerosis should take as more information becomes available. [WATCH TIME: 6 minutes
Identifying Reasons, Barriers to Low Employment Rates in NMOSD: Farrah Mateen, MD, PhDMarch 1st 2023
The associate director of the Multiple Sclerosis & Neuromyelitis Optica Unit at Massachusetts General Hospital provided perspective on a study that linked NMOSD to increased unemployment and decreased income. [WATCH TIME: 6 minutes]
Positive Response of Telehealth as Additional Option for Care in MS: Marisa McGinley, DOFebruary 28th 2023
The staff neurologist from the Mellen Center for MS Treatment and Research at the Cleveland Clinic discussed how patients with multiple sclerosis are more open to using telehealth for accessing their healthcare providers at the 2023 ACTRIMS Forum. [WATCH TIME: 4 minutes]
Differentiating Severe Multiple Sclerosis Through a Comprehensive Assessment: Robert Zivadinov, MD, PhDFebruary 28th 2023
The director of the Buffalo Neuroimaging Analysis Center provided context on the CASA-MS study, and the key differences in why certain patients with multiple sclerosis experience more rapid disability progression. [WATCH TIME: 4 minutes]
Metabolic Changes, Cognitive Improvements in Multiple Sclerosis Observed Through Intermittent Calorie RestrictionFebruary 27th 2023
Compared with those on an unrestricted diet, patients with MS on intermittent calorie restriction showed greater cognitive performance, as assessed by SDMT, after 12 weeks dieting.
Building Trust and Increasing Patient Engagement With MS Communities: Marisa McGinley, DOFebruary 27th 2023
At the 2023 ACTRIMS Forum, the staff neurologist from the Mellen Center for MS Treatment and Research at the Cleveland Clinic talked about the lack of trust and engaging more with the MS community. [WATCH TIME: 5 minutes]
Access to MS Care in Underserved and Diverse Populations: Marisa McGinley, DOFebruary 26th 2023
The staff neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic, spoke at the 2023 ACTRIMS Forum about disparities in care access for patients with MS. [WATCH TIME: 5 minutes]
Long-term Ozanimod Treatment in Relapsing Multiple Sclerosis Associated With Stable or Improved Disease Activity and SafetyFebruary 26th 2023
An ad hoc analysis of patients from a pair of phase 3 clinical trials and an open-label extension suggest that more than 5 years of treatment with ozanimod (Zeposia; BMS) was safe, without differences in age groups.